Text Size

Treatment of Disseminated High Grade Lymphoma

This study has been completed.
Sponsor:
Information provided by:
Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS
ClinicalTrials.gov Identifier:
NCT00536393
First received: September 26, 2007
Last updated: October 31, 2007
Last verified: September 2007
History of Changes
  Purpose

Interest of the use of pegylated liposomal doxorubicin (caélyx)


Condition Intervention Phase
Lymphoma
 Drug: Doxorubicin
Drug: Doxorubicin pegylated
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Study of Treatment of Disseminated and Agressive Lymphoma R CHOP Versus R CLOP( With Liposomal Doxorubicin)

Resource links provided by NLM:

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Further study details as provided by Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS:

Primary Outcome Measures:
  • hematologic toxicity [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • response rate [ Time Frame: 6 months ]
  • EFS and OS [ Time Frame: 6 months ]
  • Cardiac toxicity [ Time Frame: 6 months ]

Enrollment: 100
Study Start Date: October 2000
Study Completion Date: October 2004
Arms Assigned Interventions
Active Comparator: Doxorubicine
CHOP 8 courses every 21 days
 Drug: Doxorubicin
Experimental: Doxorubicine pegylated
CLOP 8 courses every 21 days
 Drug: Doxorubicin pegylated

Detailed Description:

R CHOP is a good standard in the treatment of diffuse high grade lymphoma. Howeverin elderly patients it is often toxic, specially with haematologic and cardiac toxicities.

  Eligibility

Ages Eligible for Study:   60 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • high grade lymphoma
  • disseminated
  • > 60 years old and < 75
  • informed consent signed
  • cardiac state compatible with antracyclin
  • ECOG </= 2

Exclusion Criteria:

  • patients > 75 years old
  • Cardiac insufficiency
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00536393

Locations
France
Clinique Victor Hugo
Le Mans, France, 72015
Sponsors and Collaborators
Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS
Investigators
Principal Investigator: Guillaume CARTRON, Dr Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00536393     History of Changes
Other Study ID Numbers: GOELAMS 0804
Study First Received: September 26, 2007
Last Updated: October 31, 2007
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS:
diffuse larg cells lymphoma
chemotherapy
toxicity
diffuse high grade lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
 Immune System Diseases
Doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 17, 2013